- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03680976
Anti-Inflammatory Lipid Mediators in Asthma (ALMA)
September 20, 2018 updated by: Sally E. Wenzel MD
The purpose of this study is to demonstrate the efficacy and safety of 10-nitro-9(E)-octadec-9-enoic acid (CXA-10) in obese adult asthmatics.
The study's hypothesis is that 150 mg/day of CXA-10 for 12 weeks will alleviate obesity-related airway hyper-reactivity in obese adult asthmatics.
Study Overview
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- The University of Pittsburgh Asthma Institute at UPMC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adequate completion of informed consent process with written documentation. Male and female patients, 18 to 65 yrs old female subjects should be either post-menopausal, surgically sterile, or women of child-bearing potential (WOCP) with a negative pregnancy test prior to entering the study and who agree to use an acceptable method of contraception, for the duration of the study.
- Diagnosis of asthma: based on previous physician diagnosis for > 6 months, and either baseline pre-bronchodilator (BD) FEV1 between 50 and 90% predicted with a 12% or greater bronchodilator response to 4 puffs of albuterol or PC20 methacholine (16 mg) if no BD response (<12% change), within 2 years of Visit 0. If no historical reversibility or historical PC20, and the participant does not reverse 12% at V0, the participant can return for V0a to meet this eligibility criteria.
- Daily treatment with inhaled corticosteroids and long acting beta agonists (ICS/LABA) combination medication for at least 3 months; on a stable dose for the 4 weeks prior to Visit 0
- Asthma control questionnaire ACQ > 1.5 & ≤ 3
- Smoking history <10 pack years and no smoking in the last year
- Body Mass Index (BMI) ≥ 30 kg/m2
- Hemoglobin A1c (HbA1c) <8%
- Average systolic blood pressure <160 or diastolic < 100 mmHg (average of three measurements))
- Resting HR ≥45 beats per minute (BPM) after 5 minute rest at screening
- QTcF interval (Fredericia's correction factor) must be ≤430 msec at screening and pre-dose for males and ≤450 msec for females.
- For randomization: No exacerbations or treatment failures during the run in. Patients, who exacerbate or experience treatment failure during the run-in, may re-enroll 4 weeks after the exacerbation has resolved (completed course of systemic corticosteroids).
Exclusion Criteria:
- Respiratory tract infection within the last 4 weeks
- Oral or systemic corticosteroid burst within the last 4 weeks
- Asthma-related hospitalization within the last 2 months
- Three or more asthma exacerbations requiring treatment with systemic corticosteroids in the past year consistent with severe asthma
- Asthma-related ER visit within the previous 4 weeks
- Significant or uncontrolled concomitant medical illness including (but not limited to) heart disease, cancer, or diabetes at the discretion of the investigator
- History of ICU admission/intubation due to asthma in the past year
- Current statins use, patients may stop and re-enroll after 4 weeks of stopping statins
- Positive pregnancy test at screening and at pre-dose
- Women who are breastfeeding
- Women of childbearing potential who are unwilling to use an acceptable method of birth control.
- Intolerance or hypersensitivity to the CXA-10 or it's excipients
- Treatment with any investigational drug within 30 days or 5 half-lives (whichever is longer) prior to the beginning of dosing (this includes investigational formulations of marketed products, inhaled and topical drugs
- Unable or unlikely to complete study assessments or the study intervention (i.e. bronchoscopy) poses undue risk to patient in the opinion of the Investigator;
- Any kind of oral nitrates such as nitroglycerin
- Any clinical history of cardiovascular events, arrhythmias, fainting, palpitations within the previous 3 years
- Personal or family history of congenital prolonged QT syndromes or sudden unexpected death due to a cardiac reason
- History of any primary malignancy, including a history of melanoma or suspicious undiagnosed skin lesions, with the exception of basal cell or squamous cell carcinomas of the skin
- Cervical carcinoma in situ or other malignancies curatively treated and with no evidence of disease for at least 5 years
- History of alcohol or drug abuse in the 6 month period prior to enrollment
- Treatment with vitamins, herbal and dietary supplements within 7 days or 5 - ½ lives whichever is longer prior to dosing until the final study visit, whichever is longer prior to dosing until the final study visit. (may rescreen after a washout)
- Resting heart rate ≥100 BPM after 5 minutes rest at screening
Subjects with any other clinically relevant ECG parameter abnormality (e.g., PR interval, QRS deviation) or any clinically significant ECG abnormality will be excluded from the study. Any clinically significant abnormalities on 12-lead ECG at screening including, but not limited to any of the following:
- PR interval >200 msec or <120 msec
- Non-specific intra-ventricular conduction delay (IVCD) with QRS duration ≥110 msec and where the morphology does NOT meet criteria for left (LBBB) or right bundle branch block (RBBB)
- Incomplete RBBB as defined by QRS duration ≥110 msec but <120 msec with RBBB pattern
- Complete RBBB and LBBB
- Evidence of second- or third- degree AV block
- Pathological Q-waves (Q-wave wider than 0.04 sec or depth greater than 0.4-0.5 mV)
- Evidence of ventricular pre-excitation
- Evidence of left axis deviation (left axis deviation is -30 to -90 degrees) but not normal leftward axis, ST-T wave abnormalities, LBBB and/or RBBB
- Any clinically significant murmurs evident on auscultation of the heart (including evidence of mitral valve prolapse)
- Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3.0X upper limit of normal (ULN), gamma-glutamyl transferase (GGT) >3X ULN, and total bilirubin >2X ULN. If all liver function tests (LFTs) are within normal limits (WNL) and total bilirubin is elevated, examination of direct and indirect bilirubin may be conducted. Subjects with indirect total bilirubin up to 3X ULN are presumed to have Gilbert's syndrome and may be enrolled if all other LFTs are WNL
- Any other condition and/or situation that causes the Investigator to deem a subject unsuitable for the study (e.g., due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures)
- Diagnosis of HIV
- Patients with multiple sclerosis on dimethyl fumarate (tecfidera)
- Patients with asthma on biological therapy (i.e. mepolizumab, omalizumab)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 10-nitro-octadeca-9-enoic acid (CXA-10)
CXA-10 150 mg tablet taken orally once a day for 12 weeks
|
Liquid-filled capsule containing 150 mg CXA-10 in super refined olive oil.
Other Names:
|
Placebo Comparator: Placebo
Placebo 150 mg tablet taken orally once a day for 12 weeks
|
Liquid-filled capsule containing olive oil manufactured to mimic CXA-10 150 mg capsule
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in airway responsiveness after treatment with CXA-10 using a methacholine challenge test
Time Frame: 12 weeks
|
Measured by the response to administration of methacholine.
The PC20 is a calculated value of the amount of methacholine required to cause a 20% fall in the subject's FEV1.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment with CXA-10 compared to baseline: Change in the concentration of Nitrite/Nitrate (NO2/NO3). and NO2-Conjugated Linoleic Acid (CLA) in plasma and urine
Time Frame: 12 weeks
|
Measured using analysis of plasma and urine at baseline and after treatment with CXA-10.
|
12 weeks
|
Treatment with CXA-10 compared to baseline: Characterization of the pharmacokinetic (PK) profile of CXA-10 in plasma and urine
Time Frame: 12 weeks
|
Measured using analysis of plasma and urine at baseline and after treatment with CXA-10.
|
12 weeks
|
Treatment with CXA-10 compared to baseline: Changes in airway epithelial gene expression
Time Frame: 12 weeks
|
Measured using bronchial samples from the subjects randomized to undergo a bronchoscopy
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sally E Wenzel, MD, The University of Pittsburgh
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Primary Completion (Anticipated)
April 1, 2021
Study Completion (Anticipated)
April 1, 2021
Study Registration Dates
First Submitted
March 9, 2016
First Submitted That Met QC Criteria
September 20, 2018
First Posted (Actual)
September 21, 2018
Study Record Updates
Last Update Posted (Actual)
September 21, 2018
Last Update Submitted That Met QC Criteria
September 20, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO16020149
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on CXA-10
-
Complexa, Inc.Philips Healthcare; Medpace, Inc.; Allegheny Singer Research Institute (also... and other collaboratorsTerminatedPAHUnited States, United Kingdom
-
Complexa, Inc.Completed
-
Complexa, Inc.CompletedAcute Kidney InjuryUnited States
-
Complexa, Inc.Completed
-
Complexa, Inc.Medpace, Inc.; MicroConstants; Kidney Research Network, formerly NephCure Accelerating... and other collaboratorsCompletedPrimary Focal Segmental GlomerulosclerosisUnited States
-
Complexa, Inc.Medpace, Inc.; Allegheny Singer Research Institute (also known as Allegheny... and other collaboratorsTerminated
-
Gladwin, Mark, MDNational Heart, Lung, and Blood Institute (NHLBI); Complexa, Inc.Terminated
-
University of Colorado, DenverNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...RecruitingObesity | AsthmaUnited States
-
Complexa, Inc.CompletedOpen-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney InjuryAcute Kidney Injury (Nontraumatic)United States
-
Cubist Pharmaceuticals LLCCompletedComplicated Urinary Tract InfectionUnited States, Germany, Poland